Injectable gel effective in treating head and n...( ks with weekly evaluations for four wee...),Health

Tumors responded in 35 of 119 patients receiving the cisplatin/epinephrine gel (29 percent). Twenty-three (19 percent) had complete responses with the cisplatin/epinephrine gel vs. 2 percent for those in the placebo gel groups (1 in 59 patients). Patients in the treatment group also met more of their treatment goals (27 percent vs. 12 percent in the placebo group). Treatment goals included improved pain control, improved wound care, relief of symptoms and better physical appearance.

"In these two randomized, double-blind, placebo-controlled phase II trials, cisplatin/epinephrine gel was shown to be effective in producing clinically meaningful response and palliative benefit in a group of patients with advanced HNSCC who had few, if any, remaining therapeutic options. Moreover, the strong association between response and patient benefit clearly demonstrated the advantage of treatment over placebo," the authors write.

'"/>

Contact: Elizabeth Crown
312-503-8928
JAMA and Archives Journals
14-Aug-2002